Akebia Therapeutics Enters Material Definitive Agreement
Ticker: AKBA · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, partnership
Related Tickers: AKBA
TL;DR
Akebia just signed a big deal, details TBD.
AI Summary
On April 15, 2024, Akebia Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its counterparty, or any associated financial terms.
Why It Matters
This filing indicates a significant new contract or partnership for Akebia Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement.
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Registrant
- April 15, 2024 (date) — Date of earliest event reported
- 245 First Street Cambridge, Massachusetts 02142 (address) — Principal executive offices
- 617-871-2098 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Akebia Therapeutics?
The filing does not specify the nature of the agreement, only that a material definitive agreement was entered into on April 15, 2024.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the agreement.
Are there any financial terms or obligations associated with this agreement?
The filing does not provide any details regarding financial terms or obligations related to the agreement.
When was the material definitive agreement entered into?
The agreement was entered into on April 15, 2024.
What is the purpose of this 8-K filing?
This 8-K filing is to report the entry into a material definitive agreement by Akebia Therapeutics, Inc.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-04-16 07:33:59
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital Marke
Filing Documents
- akba-20241504xwuxiamendment.htm (8-K) — 25KB
- 0001517022-24-000033.txt ( ) — 26KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on April 2, 2020, Akebia Therapeutics, Inc. (the "Company") entered into a Supply Agreement with STA Pharmaceutical Hong Kong Limited, a Hong Kong corporation ("STA"), as amended on April 15, 2021 (as amended, the "Supply Agreement"), under which STA manufactures vadadustat drug substance ("Product") for the Company's commercial purposes. On April 15, 2024, the Company and STA entered into Amendment #2 to the Supply Agreement (the "Amendment"). Pursuant to the Amendment, the term of the Supply Agreement is extended for an additional five (5) years and expires on April 2, 2029. In addition, the Amendment amends the volume-based pricing structure under the Supply Agreement. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which the Company expects to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AKEBIA THERAPEUTICS, INC. Date April 16, 2024 By s John P. Butler Name John P. Butler Title President and Chief Executive Officer